HomeCompareTMBR vs KMB

TMBR vs KMB: Dividend Comparison 2026

TMBR yields 583.77% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TMBR wins by $207588.12M in total portfolio value
10 years
TMBR
TMBR
● Live price
583.77%
Share price
$0.34
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207588.17M
Annual income
$155,267,282,426.18
Full TMBR calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — TMBR vs KMB

📍 TMBR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTMBRKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TMBR + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TMBR pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TMBR
Annual income on $10K today (after 15% tax)
$49,620.55/yr
After 10yr DRIP, annual income (after tax)
$131,977,190,062.25/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, TMBR beats the other by $131,977,185,623.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TMBR + KMB for your $10,000?

TMBR: 50%KMB: 50%
100% KMB50/50100% TMBR
Portfolio after 10yr
$103794.11M
Annual income
$77,633,643,824.26/yr
Blended yield
74.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

TMBR
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-39.2
Piotroski
1/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TMBR buys
0
KMB buys
0
No recent congressional trades found for TMBR or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTMBRKMB
Forward yield583.77%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$207588.17M$45.9K
Annual income after 10y$155,267,282,426.18$5,222.34
Total dividends collected$203195.85M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: TMBR vs KMB ($10,000, DRIP)

YearTMBR PortfolioTMBR Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$69,077$58,377.12$11,314$614.45+$57.8KTMBR
2$450,784$376,871.29$12,867$760.19+$437.9KTMBR
3$2,780,833$2,298,494.08$14,713$945.27+$2.77MTMBR
4$16,227,026$13,251,534.56$16,924$1,181.90+$16.21MTMBR
5$89,630,986$72,268,068.54$19,596$1,486.64+$89.61MTMBR
6$468,967,935$373,062,780.07$22,850$1,882.16+$468.95MTMBR
7$2,326,040,505$1,824,244,814.49$26,849$2,399.80+$2326.01MTMBR
8$10,945,028,688$8,456,165,347.80$31,812$3,083.36+$10945.00MTMBR
9$48,898,024,515$37,186,843,819.07$38,033$3,994.72+$48897.99MTMBR
10$207,588,168,658$155,267,282,426.18$45,918$5,222.34+$207588.12MTMBR

TMBR vs KMB: Complete Analysis 2026

TMBRStock

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.

Full TMBR Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this TMBR vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TMBR vs SCHDTMBR vs JEPITMBR vs OTMBR vs KOTMBR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.